Trial Profile
An Open Label Phase 1 Study of SC-006 as a Single Agent and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Jul 2020
Price :
$35
*
At a glance
- Drugs SC 006 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; First in man
- Sponsors AbbVie
- 24 Jun 2020 Results presented at the 111th Annual Meeting of the American Association for Cancer Research - II
- 25 Apr 2019 Status changed from completed to discontinued.
- 05 Apr 2019 Status changed from active, no longer recruiting to completed.